hOMCs for the treatment of neurological diseases
Sandu Pitaru has IP related to human oral mucosal stem cells. He will collaborate with Dani Offen to study the application of these cells in neurological disease. Project ID : 2-2011-173
Summary of the technology
Sandu Pitaru has IP related to human oral mucosal stem cells. He will collaborate with Dani Offen to study the application of these cells in neurological disease.
Project ID : 2-2011-173
A novel pluripotent stem cell population, termed hOMSCs, has been isolated from adult human oral mucosa. The hOMSC population expresses markers of pluripotent embryonic stem cells and of multipotent mesenchymal stem cell markers. hOMSCs form the majority of primary oral mucosa-derived populations grown in culture. Thus, their clinical use does not require cumbersome and expensive isolation/purification steps. A biopsy of a 4-5 mm2 from the oral mucosa is sufficient for generating 109 hOMSCs in a few weeks. Biopsy harvest is extremely simple, time-and cost-efficient, causes minimal morbidity to the patient and can be repeated unlimitedly. Furthermore, the frequency and "stemness" of hOMSCs is unaffected by the age of the patient.
Both in vitro and in vivo studies using these cells have demonstrated their efficacy and safety in different indications.
Mesodermal lineages (vascular tissue; bone; cartilage; muscle); Ectodermal lineages (Neurons; glia cells); Endoderm (Definitive endoderm – future development to pancreatic and hepatic lineages)